France Redefines Diagnostic Reimbursement with the First AI-Enabled and Genomic Tests Under RIHN 2.0 Introduction France is now setting the pace for evidence-linked reimbursement of diagnostics. Under RIHN 2.0, public …

France’s Bold Frontier: How the Early Access Programme (AAP) is Redefining Hope, Access, and Reimbursement in 2025. It is one of the most sophisticated early access and temporary reimbursement frameworks …

Article 51 of the Loi de Financement de la Sécurité Sociale (LFSS 2018) is the most flexible, strategic, and scientifically grounded mechanism France has created to transform care delivery using …

In 2024, the Netherlands introduced what is now widely regarded as the most scientifically rigorous health-economic evaluation guideline in Europe. For companies preparing submissions in 2025, the key issue is …

Learn how IVD reimbursement works in France in 2025. Understand NABM, LAHN and RIHN 2.0, and how innovative diagnostics move from pilots to national tariff. Reimbursement of In Vitro Diagnostic …

Discover how Europe’s new 2025 framework will evaluate AI, SaMD and digital medical devices, with harmonised HTA, evidence standards and pathways to reimbursement. Artificial intelligence is now at the centre …